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48
Introduction 49 Euthyroid multinodular goiter (MNG) is common and affects at least 4% of the population, although the 50 prevalence varies with ethnicity and the detection method employed (1). Furthermore, nodular goiter is far 51 more prevalent in iodine deficient regions (2) . Although solitary nodules are considered a risk for thyroid 52 cancer (3) the situation for MNG is more controversial (4); the reported increase in the incidence of some 53 thyroid cancers (5) may, in part, be due to increased use of diagnostic tools (6) . BRAF mutations causing 54 constitutive activation are the most frequent driver of papillary thyroid cancer (PTC) (7) . Several genetic 55 variations lead to sporadic thyroid cancers including, among others, RET chromosomal re-arrangements 56 (8) , translocations between chromosome 2 and 3 generating a PPARγ-PAX8 fusion protein (9), mutations 57 in RAS genes (10) and poly-alanine tract length variation in FOXE1 (11, 12) .
58
Familial non-medullary thyroid cancers account for about 5% of thyroid cancers and have a younger age 59 of onset than sporadic disease. They are associated with 4 susceptibility loci (13-16) on chromosomes 60 19p13.2, 2q21, 1q21 and 10q23 (PTEN). There is some overlap with familial goiter in which 8 predisposing 61 loci have been identified (12, (17) (18) (19) (20) on chromosomes Xp22, 3q26, 2q, 3p, 7q, 8p 14q13.3 and 14q32, the 62 last two including the NKX2.1 (21) and the RNAse DICER1 genes respectively (22) . A role for the 63 predisposing loci on chromosomes 2q. 35, 5q.24, 8p.12 and 14q.13 has been confirmed in Chinese families 64 (23) . Genes implicated in familial goiter and cancer generally differ from those in sporadic disease, with 65 the exception of NKX2.1 (21) and FOXE1 (24).
66
Previously, we reported a family (25) exhibiting a type of euthyroid MNG with papillary adenomas of 67 adolescent onset affecting 8 individuals in 4 generations to date. MNG is known to have progressed to PTC 68 in 2 of the 8 affected family members. We applied microsatellite analysis to exclude loci described above 69 on chromosomes 14q, Xp, 3q 9p, 2q and 1q. Since one family member had co-existing breast cancer and 70 another co-existing kidney disease we investigated genes co-expressed in these tissues and the thyroid, NIS 71 and PAX8 respectively. Sanger sequencing revealed no abnormality in either gene. Subsequently, the PTEN 72 gene has been fully sequenced in the family member with breast cancer and no mutations were detected.
73
The aim of this study was to apply genome-wide linkage analysis (GWLA) and next generation 74 sequencing to identify the gene variant(s) responsible for the observed phenotype in this family. We then 75 aimed to assess the frequency of any variant(s) detected in other relevant cohorts.
77

Subjects and Methods
79
Genome-Wide Linkage Analysis (GWLA)
80
We undertook a GWLA of the family described in (25) and summarized in figure 1.
81
All patient samples were obtained with informed consent and Local Research Ethics Committee (LREC) 82 approval. Genomic DNA was extracted from whole blood from 18 family members (those labelled in the 83 tree) of whom 8 were affected (7 females, 1 male), according to the manufacturer's instruction (Qiagen) 84 and quantified using a Nanodrop. Samples (250 ng) were processed following the manufacturer's protocol 85 and the DNA integrity monitored by agarose gel electrophoresis before being hybridized at 48°C for 18 86 hours to Affymetrix Genechip™ Human Mapping 10K 2.0 Arrays. The chips were scanned using an 87 Affymetrix GeneChip scanner 3000; data were acquired using GCOS and analyzed using GTYPE software 88 respectively.
89
Two quality control steps were performed; the first eliminated SNPs showing 'no call' in more than 4 90 individuals. The second step would have eliminated data from any individual with >10% 'no calls', but this 91 did not apply and the data of all 18 family members were retained. 99 penetrance in females, 50% in males and age of onset later than 12 years (based on clinical information 100 summarized in figure 1). Single point analyses were also used to support the findings of multipoint analysis.
101
Since data are derived from a single large family, there is considerable allele sharing and hence the Kong 
131
Other variants identified in the family using NGS were interrogated in the SHIP cohort (Study of Health in 132 Pomerania) (28). Relevant genotyping data were available from 986 individuals who were either unaffected 133 or presented with diffuse goiter (as defined in (29)) and/or MNG (nodules identified by ultrasound). 
152
We developed a qPCR based genotyping tool using primers within and flanking the PLCB1 InDel as 153 described above (Supplementary table 2 
207
Subsequently, genomic DNA was extracted from thyroid tissue from 70 patients undergoing surgery for 208 non-familial PTC and an additional 81 operated for non-familial MNG. We used PCR analysis to test for 209 the InDel, as described above. The InDel was not detected in any of the PTC patients but 4 of the 81 MNG 210 were heterozygous for the InDel and sequencing revealed the same ATAA insertion at the junction.
211
Comparison of the frequency of the InDel in the general population with that in MNG gives a X 2 value of 212 5.076 (1 degree of freedom), p= 0.024 (two-tailed). The 4 MNG patients (3 women, 1 man) are unrelated 213 and with no apparent family history of MNG or PTC at the time of their surgery. The age at thyroidectomy 214 was between 27 to 59 years and the pathology is variously described as 'oncocytic neoplasm with variable 215 patterns of growth' to 'cystic degeneration with calcification'. We also investigated whether the PLCB1 216 InDel might be implicated in breast cancer using the qPCR-based screening protocol. Prevalence in this 217 cohort was similar to that of the general population, i.e. 1%, since just 2 breast cancer patients harbored the 218 PLCB1 InDel.
220
Next Generation Sequencing of the Chr20 high LOD score region 221 The Proton Sequencer generated 9.9 Gbp of data, achieving 98% accurately mapped sequences with >88% 222 of the percentage of target bases covered by at least 0.2 times the average base read depth.
223
A total of 181 sequence variants between Chr20 8113405 and 11907285 were identified in the family with 224 the minor allele being on the disease risk haplotype in 12 of these. Given the rarity of PTC and the expected 225 high penetrance, we expect a pathogenic variant to have a very low population frequency. After referring 226 to the UCSC genome browser, only 1 of the 12 variants was found to have a minor allele frequency <1%; 227 its presence in affected family members was confirmed by Sanger sequencing. The variant is at Chr20 228 10036484 (rs56234782) with T (98.8%) or C (1.2%) in the 3' UTR of the ANKRD5 gene. To investigate 229 whether it is implicated in goiter and/or thyroid nodule formation, we investigated its frequency in the SHIP 230 cohort. However, even though the minor allele was more prevalent in the entire cohort, the prevalence in 231 the affected population (goiters 1.9% and nodules 2.54%) was lower than in the unaffected populations 232 (2.79% and 2.85% respectively), thereby excluding a role for it in MNG.
233
The MNG cohort was also submitted to NGS analysis. This identified more than 300 different sequence 234 variants across the 80 patients, however, all were also present in the 1000 genomes cohort at a population 235 frequency >1%. We therefore considered it unlikely that any of these variants are pathologically relevant 236 to MNG, thereby confirming the relevance of the InDel. 
243
PLCB1 is present in several isoforms including PLCB1-a and PLCB1-b, with the latter having a 244 predominantly nuclear location (33). To test the hypothesis that the InDel causes preferential transcription 245 of certain PLCB1 isoforms, RNA was extracted from thyroids from the original family and from subjects 246 undergoing thyroidectomy for benign disease. In all cases genomic DNA from the donor thyroid was tested 247 for the PLCB1 deletion.
248
QPCR analysis of InDel-affected thyroids did not indicate altered expression of the major PLCB1 isoforms 249 a and b (sequenced to confirm they were wild type, data not shown). However, qPCR measurements 
260
The InDel comprises the loss of 1077 bp with an ATAA inserted at the junction in all affected family 261 members and the 4 unrelated patients with MNG. We suggest that this may indicate a 'cut and paste' event 262 indicating transposon activity. Interestingly, a 11-kb transposon cluster has been identified immediately 263 upstream of the 3.7 Mbp section on chr 20 displaying a non-parametric LOD score of 3.01 in the current 264 study (34). Of note the LOD score of 3.01, whilst at the lower limit to be considered significant, is higher 265 than the maximum estimated for a kindred having 8 affected individuals (35).
266
We detected the same InDel in 1 subject of a selected cohort of 105 people in whom measuring thyroid 267 function was clinically indicated. We also consulted the database of genomic variants and found several 268 reports of relevance. Conrad et al. found the deletion in 2 of 180 Caucasians but insufficient detail is 269 provided to know whether it is a simple CNV or the same InDel identified in our studies. Combining our 270 genotyping data with that of Conrad et al. reveals that 3 in 285 Caucasians harbor the deletion, suggesting 271 that it is rare (31). Several other authors did not observe this deletion, but aware of the difficulty in detecting 272 small CNVs, we did not include these in our calculation. In addition, 200 patients with breast cancer have 273 been screened for the InDel with only two harboring this deletion. Hence, the prevalence was similar to the 274 general population suggesting that there is no connection of the InDel with breast cancer.
275
We then considered how the deletion or novel PLCB1 InDel might exert its effects. The region was 276 explored using the Encyclopedia of DNA elements (ENCODE) (although compiled without inclusion of 277 thyroid tissue or cell lines) (36), which revealed the existence of a binding site for the estrogen receptor 278 alpha (ERα) within the deletion. This is of potential importance since all thyroid diseases are more prevalent 279 in women than men (1). The incidence of thyroid disorders increases in the years immediately following 280 puberty and in vitro studies have demonstrated that estrogen can promote thyrocyte proliferation (37) by 281 several mechanisms. The PLCB1 InDel is located in an intron; while many functional transcription factor 282 binding sites are found in promoters, a systematic search for ERα binding sites in the human genome 283 identified >1000 with >95% of them residing in introns and not promoters (38).
284
We also conducted experiments to determine whether the deletion alters the ratio of PLCB1-a and PLCB1-285 b, which are generated by alternative splicing. Differences in their C terminal sequence mean that only 286 PLCB1-a has a nuclear export signal. We found no alteration in the ratio of PLCB1-a and b isoforms but 287 in all cases transcript levels for PLCB1 were higher in thyroids from people heterozygous for the InDel 288 than in thyroids with two full-length copies. This suggests that the InDel may contribute to MNG 289 development through overexpression of PLCB1. Furthermore, total PLC enzyme activity is elevated in 290 thyroid neoplasms (39) but unfortunately PLC inhibitors lack the specificity required to identify which 291 isoform is responsible. Increased PLCB1 expression has also been reported in small cell lung carcinoma 292 (40) and expression of PLCB2 is substantially increased in breast cancer and is used as a prognostic marker 293 (40).
294
As mentioned above, PLC enzymes activate PKC and genes implicated in this signal pathway are 295 upregulated in euthyroid MNG (41). They also link signaling via Gq (which can also be activated via the 296 thyrotropin receptor) to the MAPK cascade and in the thyroid disruption of this pathway, by thyrocyte-297 targeted Cre/Lox P knock-down of the Gqα subunit, produces mice which are resistant to goiter formation 298 when fed a goitrogenic diet (42). However, when we performed western blots with protein extracts of 299 thyroid tissue from family members with the PLCB1 InDel we were surprised to observe that pMAPK 300 levels were substantially lower than in thyroid tissue from patients with autoimmune thyroid disease or 301 MNG without the PLCB1 InDel ( Supplementary Figure 5 ).
302
In conclusion, the PLCB1 InDel identified in this family with MNG also occurs in a proportion of sporadic 303 MNG, and may provide a biomarker to identify MNG patients more likely to progress to PTC. The PLCB1 304 InDel appears to predispose to goiter formation, possibly by increasing PLCB1 transcription with 305 subsequent downstream effects. 
